Espervita

Espervita is a startup based in the United States. Brouky classifies it under Healthcare & Life Sciences.

Espervita Therapeutics develops first-in-class acetyl-CoA metabolic enzyme inhibitors targeting metabolic diseases such as steatohepatitis, chronic kidney disease, and liver fibrosis, with a lead compound demonstrating efficacy in preclinical models.